Key result
Accumulated evidence from randomized trials supports the preferential use of prasugrel over ticagrelor in appropriately selected patients with acute coronary syndromes undergoing PCI.
Why the study?
Does prasugrel improve outcomes compared to ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Does prasugrel improve outcomes compared to ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention?
Answers are grounded in this paper and cite their sources.
Based on recent large randomized trials, prasugrel should be preferentially used over ticagrelor in appropriately selected patients with ACS undergoing PCI, challenging their identical guideline positioning.
Prasugrel and ticagrelor are potent oral P2Y12 inhibitors that carry a Class I recommendation for patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), providing faster and more consistent platelet inhibition than clopidogrel.(1,2) Despite identical guideline positioning, the optimal choice between the two agents has long remained unsettled, largely because head-to-head randomized data were scarce and the agents were assumed to be clinically interchangeable.(3,4) That assumption is now substantially challenged by two large randomized trials (ISAR-REACT 5 and TUXEDO-2) whose convergent findings consistently point in the same direction. Here, we argue that the accumulated pharmacological and clinical evidence builds a coherent, mechanistically grounded case for the preferential use of prasugrel in appropriately selected patients, and that persisting therapeutic inertia against this drug is no longer scientifically defensible.
No takes yet. Share an insight, caveat, or question.
Prezzavento et al. (2026) conducted an editorial in Acute coronary syndromes (ACS) undergoing PCI. Prasugrel vs. Ticagrelor was evaluated. Accumulated evidence from randomized trials supports the preferential use of prasugrel over ticagrelor in appropriately selected patients with acute coronary syndromes undergoing PCI.
Synapse has enriched 10 related papers. Consider them for comparative context: